Broadcasting the latest developments in GU cancer Hosted by Brian Rini and Tom Powles Brian Rini MD is Chief of Clinical Trials, Professor of Cancer Research and Professor of Medicine (Hematology/Oncology), Vanderbilt-Ingram Cancer Centre Tom Powles is Director of Barts Cancer Centre, St Bartholomews Hospital and Professor or Genitourinary oncology, Queen Mary University of London
…
continue reading
What to see at the ASCO 2024 Annual Meeting, with Silke Gillessen.
…
continue reading
Nick James discusses this paper, which covers broad issues in prostate cancer - including diagnosis and treatment with a focus on the future.
…
continue reading
David Penson discusses highlights for the upcoming meeting. He articulates his excitement around the NMIBC data.
…
continue reading
Silke covers key aspects of the meeting, including surgery vs RT, genetic and somatic testing, PSMA imaging and 1st line triplet therapy.
…
continue reading
1
Episode 315: APCCC 2024 Quickfire - Bone health, hot flashes and gynecomastia in prostate cancer
18:17
Chris Sweeney is joined by Matt Smith, Anthony Joshua and Lisa Horvath to discuss the management of these complex issues in advanced prostate cancer.
…
continue reading
Thomas Suter and Chuck Ryan discuss identification and management of cardiovascular disease for patients starting therapy for prostate cancer.
…
continue reading
Thomas Zilli and Pierre Blanchard discuss this topic from Lugano.
…
continue reading
Jason Efstathiou and Piet Ost discuss the data for and against this approach.
…
continue reading
Alison Birtle describes adjuvant chemotherapy in bladder cancer.
…
continue reading
Daniel Goldstein describes his work on this issue.
…
continue reading
In this second part, Matt Galsky describes the OS signal data. We also look into the future.
…
continue reading
Tom, Brian and Matt Galsky review the screening component of this study, presented at EAU24.
…
continue reading
Michiel Van der Heijden explores the role of radiotherapy and other neoadjuvant and other neoadjuvant combinations to prevent the need for surgery.
…
continue reading
1
Episode 306: The Uromigos Paper of the Month - Chemo/Nivo as a bladder sparing approach in UC
29:56
Matt Galsky describes his phase 2 study looking at gem/cis/nivo followed by nivo in responders. This potentially avoids cystectomy.
…
continue reading
FDA Deputy Oncology Director Dan Suzman described approaches to oncology trials. Tom asks 3 last questions which annoys Brian more than usual.
…
continue reading
Tanya Dorff describes acapatamab, a prostate-specific membrane antigen (PSMA) CD3 bispecific engager.
…
continue reading
Michael Lattanzi discusses treatment plans and research in the community.
…
continue reading
Hans Hammers discusses trial design and patient selection in the adjuvant setting.
…
continue reading
Vania Wisdom, editor of the Lancet, talks about approaches to cancer treatment and research in developing countries
…
continue reading
David McDermott discusses melanoma and renal data. We never get to bladder or lung.
…
continue reading
Dana Rathkopf describes phase 1 data for the androgen receptor ligand-directed degrader in prostate cancer
…
continue reading
Silke, Tom and Brian cover the bases.
…
continue reading
Neeraj Agarwal addresses the issues raised at the meeting.
…
continue reading
Cris Bergerot describes her modifications of existing QOL models while Tom describes the QOL data from LS005
…
continue reading
Pedro Barata summarises his ASCO GU discussion on this topic.
…
continue reading
Andrea Apolo describes the results of this positive trial.
…
continue reading
Kim Chi discussed the prostate cancer oral session at ASCO GU 2024.
…
continue reading
Misha Beltran describes the activity of this novel agent in neuroendocrine prostate cancer.
…
continue reading
Neeraj Agarwal describes the results of this positive randomised Phase 3 trial.
…
continue reading
What to look out for in bladder, prostate and renal cancer at this year's meeting.
…
continue reading
Karim Fizazi discusses the clinical and biomarker components of this data.
…
continue reading
Thomas Zilli discusses controversies around radiotherapy in prostate cancer.
…
continue reading
Silke Gillessen and Betrand Tombal discuss the questions which will address this issue in Lugano in March 2024.
…
continue reading
Silke Gillessen discusses this biannual meeting taking place in Lugano in March 2024.
…
continue reading
Cristina Suarez discusses the year in review.
…
continue reading
Elena Castro, Begoña Valerrama y Cristina Suárez analizan lo más destacado del cáncer en urología en 2023
…
continue reading
Tanya Dorff discusses her favourite prostate cancer studies of the year.
…
continue reading
Kala Sridhar discusses all the key trials in 2023. She also reveals her favourite Xmas song.
…
continue reading
Rahul Aggarwal describes his phase 1/2 study with only 1 cycle of Lu-177 in CRPC.
…
continue reading
Tian Zhang discusses this fabulous renal cancer meeting. Belzutifan is covered too.
…
continue reading
Tom and Brian apologise for the unacceptable words and images which were broadcast by hackers during the Uromigos livestream last week. We’re really sorry and will do everything we can to make sure it never happens again.
…
continue reading
1
Episode 279: Management of IO-resistant RCC at #UromigosLive 2023
1:00:37
1:00:37
Αναπαραγωγή αργότερα
Αναπαραγωγή αργότερα
Λίστες
Like
Liked
1:00:37
Monty Pal, Toni Chouieri, and Tian Zhang join Tom and Brian to discuss CONTACT-03, TiNivo-2, IO-based therapy, and more.Recorded live at Uromigos Live & Unplugged 2023 in Nashville, TN.
…
continue reading
Brian is joined by Neeraj Agarwal, Tanya Dorff, Rana McKay, and Michael Morris to review the state of radioligand therapy. The panel examines primary and secondary end points of VISION, current practice patterns, the right way to dose 177Lu-PSMA, PSMAfore, and more.Recorded live at Uromigos Live & Unplugged 2023 in Nashville, TN.…
…
continue reading
Tom is joined by Sam Chang, Sia Daneshmand, and Petros Grivas to discuss new therapies in non-muscle invasive bladder cancer, including those for BCG-refractory NMIBC and the cretostimogene + pembrolizumab combo for BCG-unresponsive NMIBC. Recorded live at Uromigos Live & Unplugged 2023 in Nashville, TN.…
…
continue reading
Silke Gillessen joins Tom and Brian to give a summary of the meeting,
…
continue reading
Brian and Tom discuss the benefits and risks of participating in the upcoming meeting . Uncertainty around it’s success are highlighted . Methods of attending remain opaque.
…
continue reading
Kevin Kelly described a Six-transmembrane epithelial antigen of the prostate 1 (STEAP1) bispecific T cell engager showing activity in a phase 1 trial in prostate cancer.
…
continue reading
Toripalimab plus axitinib as first-line treatment option for advanced RCC by Xinan Sheng
…
continue reading
Michiel van der Heijden and Tom discuss EV302 (EVP) and CM901 (chemo/nivo)
…
continue reading
Yohann Loriot described the 2 Thor randomised phase 3 studies
…
continue reading